494 related articles for article (PubMed ID: 29972739)
1. Benralizumab for the add-on maintenance treatment of patients with severe asthma aged 12 years and older with an eosinophilic phenotype.
Al Efraij K; FitzGerald JM
Expert Rev Clin Pharmacol; 2018 Jul; 11(7):669-676. PubMed ID: 29972739
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β
Bleecker ER; FitzGerald JM; Chanez P; Papi A; Weinstein SF; Barker P; Sproule S; Gilmartin G; Aurivillius M; Werkström V; Goldman M;
Lancet; 2016 Oct; 388(10056):2115-2127. PubMed ID: 27609408
[TBL] [Abstract][Full Text] [Related]
3. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.
Castro M; Wenzel SE; Bleecker ER; Pizzichini E; Kuna P; Busse WW; Gossage DL; Ward CK; Wu Y; Wang B; Khatry DB; van der Merwe R; Kolbeck R; Molfino NA; Raible DG
Lancet Respir Med; 2014 Nov; 2(11):879-890. PubMed ID: 25306557
[TBL] [Abstract][Full Text] [Related]
4. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia.
Laviolette M; Gossage DL; Gauvreau G; Leigh R; Olivenstein R; Katial R; Busse WW; Wenzel S; Wu Y; Datta V; Kolbeck R; Molfino NA
J Allergy Clin Immunol; 2013 Nov; 132(5):1086-1096.e5. PubMed ID: 23866823
[TBL] [Abstract][Full Text] [Related]
5. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
FitzGerald JM; Bleecker ER; Nair P; Korn S; Ohta K; Lommatzsch M; Ferguson GT; Busse WW; Barker P; Sproule S; Gilmartin G; Werkström V; Aurivillius M; Goldman M;
Lancet; 2016 Oct; 388(10056):2128-2141. PubMed ID: 27609406
[TBL] [Abstract][Full Text] [Related]
6. Seasonal variability of exacerbations of severe, uncontrolled eosinophilic asthma and clinical benefits of benralizumab.
DuBuske L; Newbold P; Wu Y; Trudo F
Allergy Asthma Proc; 2018 Sep; 39(5):345-349. PubMed ID: 30077185
[TBL] [Abstract][Full Text] [Related]
7. The safety of mepolizumab for the treatment of asthma.
Leung E; Al Efraij K; FitzGerald JM
Expert Opin Drug Saf; 2017 Mar; 16(3):397-404. PubMed ID: 28116937
[TBL] [Abstract][Full Text] [Related]
8. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma.
Chipps BE; Newbold P; Hirsch I; Trudo F; Goldman M
Ann Allergy Asthma Immunol; 2018 May; 120(5):504-511.e4. PubMed ID: 29409951
[TBL] [Abstract][Full Text] [Related]
9. Benralizumab: A New Approach for the Treatment of Severe Eosinophilic Asthma.
Dávila González I; Moreno Benítez F; Quirce S
J Investig Allergol Clin Immunol; 2019 Apr; 29(2):84-93. PubMed ID: 31017107
[TBL] [Abstract][Full Text] [Related]
10. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
Hilvering B; Xue L; Pavord ID
Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
[TBL] [Abstract][Full Text] [Related]
11. Two-year integrated steroid-sparing analysis and safety of benralizumab for severe asthma.
Bourdin A; Shaw D; Menzies-Gow A; FitzGerald JM; Bleecker ER; Busse WW; Ferguson GT; Brooks L; Barker P; Gil EG; Martin UJ
J Asthma; 2021 Apr; 58(4):514-522. PubMed ID: 31859541
[TBL] [Abstract][Full Text] [Related]
12. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Ferguson GT; FitzGerald JM; Bleecker ER; Laviolette M; Bernstein D; LaForce C; Mansfield L; Barker P; Wu Y; Jison M; Goldman M;
Lancet Respir Med; 2017 Jul; 5(7):568-576. PubMed ID: 28545978
[TBL] [Abstract][Full Text] [Related]
13. Benralizumab: an updated treatment of eosinophilic asthma.
Cushen B; Menzies-Gow A
Expert Rev Respir Med; 2020 May; 14(5):435-444. PubMed ID: 32133878
[No Abstract] [Full Text] [Related]
14. Antibodies targeting the interleukin-5 signaling pathway used as add-on therapy for patients with severe eosinophilic asthma: a review of the mechanism of action, efficacy, and safety of the subcutaneously administered agents, mepolizumab and benralizumab.
Hillas G; Fouka E; Papaioannou AI
Expert Rev Respir Med; 2020 Apr; 14(4):353-365. PubMed ID: 31958239
[No Abstract] [Full Text] [Related]
15. Benralizumab for the treatment of asthma.
Matera MG; Rogliani P; Calzetta L; Canonica GW; Cazzola M
Drugs Today (Barc); 2017 Dec; 53(12):633-645. PubMed ID: 29517082
[TBL] [Abstract][Full Text] [Related]
16. A Phase 2a Study of Benralizumab for Patients with Eosinophilic Asthma in South Korea and Japan.
Park HS; Kim MK; Imai N; Nakanishi T; Adachi M; Ohta K; Tohda Y;
Int Arch Allergy Immunol; 2016; 169(3):135-45. PubMed ID: 27097165
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma.
Matera MG; Calzetta L; Rinaldi B; Cazzola M
Expert Opin Drug Metab Toxicol; 2017 Sep; 13(9):1007-1013. PubMed ID: 28737051
[TBL] [Abstract][Full Text] [Related]
18. Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose.
Pelaia C; Busceti MT; Vatrella A; Rago GF; Crimi C; Terracciano R; Pelaia G
Pulm Pharmacol Ther; 2019 Oct; 58():101830. PubMed ID: 31344472
[TBL] [Abstract][Full Text] [Related]
19. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
[TBL] [Abstract][Full Text] [Related]
20. The clinical profile of benralizumab in the management of severe eosinophilic asthma.
Menzella F; Lusuardi M; Galeone C; Facciolongo N; Zucchi L
Ther Adv Respir Dis; 2016 Dec; 10(6):534-548. PubMed ID: 27612492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
